Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020

References

• Palmieri R, Paterno G, De Bellis E, et al. Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness. Cancers. 2020;12(1):120.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer stat facts: leukemia — acute myeloid leukemia (AML) surveillance, epidemiology, and end results program; 2020. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.
   Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Kopmar NE, Estey EH. New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift. Clin Adv Hematol Oncol. 2019;17(10):569–575.
   PubMed Web of Science ®Google Scholar
• Stein EM, Bonifacio G, Latremouille-Viau D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. J Med Econ. 2018;21(6):556–563.
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597–1603.
   PubMed Web of Science ®Google Scholar
• Bell JA, Galaznik A, Farrelly E, et al. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018;71:27–33.
   PubMed Web of Science ®Google Scholar
• Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV–55–61.
   Web of Science ®Google Scholar
• Segal JB, Chang HY, Du Y, et al. Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. Med Care. 2017;55(7):716–722.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27(5):997–999.
   PubMed Web of Science ®Google Scholar
• Clinformatics®. Data mart user manual version 8. Eden Prairie, MN: Optum Inc.; 2019.
   Google Scholar
• Trish E, Ginsburg P, Gascue L, et al. Physician reimbursement in Medicare advantage compared with traditional Medicare and commercial health insurance. JAMA Intern Med. 2017;177(9):1287–1295.
   PubMed Web of Science ®Google Scholar
• Zhao H, Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics. 2001;57(4):1002–1008.
   PubMed Web of Science ®Google Scholar
• Fitch K, Ferro C, Pittinger S. The cost burden of blood cancer care in Medicare: a longitudinal analysis of Medicare advantage and fee for service patients diagnosed with blood cancer: Milliman, Inc.; 2019 [cited 2021 Mar 9]. Available from: https://www.lls.org/sites/default/files/National/USA/Pdf/Milliman-Cost-Of-Blood-Cancer-In-Medicare-20191016.pdf.
   Google Scholar
• Beveridge RA, Mendes SM, Caplan A, et al. Mortality differences between traditional Medicare and Medicare Advantage: a risk-adjusted assessment using claims data. Inquiry. 2017;54:46958017709103.
   PubMed Web of Science ®Google Scholar
• Wong ES, Hebert PL, Maciejewski ML, et al. Does favorable selection among Medicare Advantage enrollees affect measurement of hospital readmission rates? Med Care Res Rev. 2014;71(4):367–383.
   PubMed Web of Science ®Google Scholar
• Lang K, Earle CC, Foster T, et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 2005;22(11):943–955.
   PubMed Web of Science ®Google Scholar
• Preussler JM, Meyer CL, Mau LW, et al. Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(6):1021–1028.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Sharma A, Chung KC, et al. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J Med Econ. 2018;21(11):1119–1130.
   PubMed Web of Science ®Google Scholar
• Irish W, Ryan M, Gache L, et al. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Curr Med Res Opin. 2017;33(3):519–527.
   PubMed Web of Science ®Google Scholar
• Pandya BJ, Chen CC, Medeiros BC, et al. Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database. J Manag Care Spec Pharm. 2020;26(7):849–859.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Wang R, Wang X, et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192–2201.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911–2919.
   PubMed Web of Science ®Google Scholar
• UnitedHealthcare Group Medicare Advance (PPO). Complete drug list (Formulary); 2021 [cited 2021 Aug 30]. Available from: https://benefits.uasys.edu/media/1680/uas_2021-medicare-advantage-plan-formulary.pdf.
   Google Scholar
• The Medicare Payment Advisory Commission. Report to the congress: Medicare payment policy: hospice services: assessing payment adequacy and updating payments. Report to the congress: Medicare payment policy. Washington (DC): The Medicare Payment Advisory Commission; 2019.
   Google Scholar